Literature DB >> 26201617

Angiogenesis: a phenomenon which aggravates chronic liver disease progression.

Michał Kukla1.   

Abstract

It has become increasingly clear that angiogenesis occurring during chronic wound healing and fibrogenesis provides a key contribution to disease progression and complications. The association of fibrogenesis and angiogenesis should be regarded as crucial in the modern evaluation of liver disease progression and in the search for therapeutic targets. Physiological hepatic angiogenesis occurs during liver regeneration, contributing to the formation of new functional sinusoids. Pathological angiogenesis in liver is characterized by intrahepatic vascular remodeling with capillarization of the sinusoids and development of intrahepatic shunts, which lead to increased hepatic resistance and decreased effective hepatocyte perfusion. The problem of angiogenesis in chronic hepatitis C and nonalcoholic fatty liver disease has not been fully resolved. This manuscript briefly describes pathogenesis of new blood vessel formation in chronic hepatitis and potential role of angiogenesis in disease progression.

Entities:  

Keywords:  Adipokine; Angiogenesis; Chronic hepatitis C; Fibrosis; Hepatic stellate cell; Inflammatory activity; Liver; Nonalcoholic fatty liver disease

Year:  2012        PMID: 26201617     DOI: 10.1007/s12072-012-9391-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  69 in total

Review 1.  Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles.

Authors:  Kenneth J Simpson; Neil C Henderson; Cynthia L Bone-Larson; Nicholas W Lukacs; Cory M Hogaboam; Steven L Kunkel
Journal:  Clin Sci (Lond)       Date:  2003-01       Impact factor: 6.124

Review 2.  A reevaluation of integrins as regulators of angiogenesis.

Authors:  Richard O Hynes
Journal:  Nat Med       Date:  2002-09       Impact factor: 53.440

Review 3.  Review article: angiogenesis soluble factors as liver disease markers.

Authors:  X Salcedo; J Medina; P Sanz-Cameno; L García-Buey; S Martín-Vilchez; R Moreno-Otero
Journal:  Aliment Pharmacol Ther       Date:  2005-07-01       Impact factor: 8.171

4.  Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis.

Authors:  Jesús Medina; Luis Caveda; Paloma Sanz-Cameno; Alicia G Arroyo; Samuel Martín-Vílchez; Pedro L Majano; Luisa García-Buey; Francisco Sánchez-Madrid; Ricardo Moreno-Otero
Journal:  J Hepatol       Date:  2003-05       Impact factor: 25.083

5.  The potential of angiogenesis soluble markers in chronic hepatitis C.

Authors:  Xamila Salcedo; Jesús Medina; Paloma Sanz-Cameno; Luisa García-Buey; Samuel Martín-Vilchez; María J Borque; Manuel López-Cabrera; Ricardo Moreno-Otero
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

6.  The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C.

Authors:  T Piche; F Vandenbos; A Abakar-Mahamat; G Vanbiervliet; E M Barjoan; G Calle; J Giudicelli; B Ferrua; C Laffont; S Benzaken; A Tran
Journal:  J Viral Hepat       Date:  2004-01       Impact factor: 3.728

7.  Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.

Authors:  Raghu Adya; Bee K Tan; Anu Punn; Jing Chen; Harpal S Randeva
Journal:  Cardiovasc Res       Date:  2007-12-18       Impact factor: 10.787

8.  Angiogenesis in chronic liver disease.

Authors:  Anjali D Amarapurkar; Deepak N Amarapurkar; S Vibhav; Nikhil D Patel
Journal:  Ann Hepatol       Date:  2007 Jul-Sep       Impact factor: 2.400

9.  Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice.

Authors:  Robert S McCuskey; Yoshiya Ito; Graham R Robertson; Margaret K McCuskey; Michael Perry; Geoffrey C Farrell
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

10.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

Authors:  Ebba Bråkenhielm; Niina Veitonmäki; Renhai Cao; Shinji Kihara; Yuji Matsuzawa; Boris Zhivotovsky; Tohru Funahashi; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

View more
  11 in total

Review 1.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Mechanisms of liver fibrosis and its role in liver cancer.

Authors:  Debanjan Dhar; Jacopo Baglieri; Tatiana Kisseleva; David A Brenner
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-10

Review 3.  Neuropilins and liver.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

4.  Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.

Authors:  Kuei-Chuan Lee; Wei-Fan Hsu; Yun-Cheng Hsieh; Che-Chang Chan; Ying-Ying Yang; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin
Journal:  Dig Dis Sci       Date:  2018-10-04       Impact factor: 3.199

Review 5.  Liver fibrosis: Pathophysiology and clinical implications.

Authors:  Jennifer Berumen; Jacopo Baglieri; Tatiana Kisseleva; Kristin Mekeel
Journal:  WIREs Mech Dis       Date:  2020-07-26

6.  Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.

Authors:  Maria-Vasiliki Papageorgiou; Emilia Hadziyannis; Dina Tiniakos; Anastasia Georgiou; Aikaterini Margariti; Athanasios Kostas; George V Papatheodoridis
Journal:  Ann Gastroenterol       Date:  2016-12-01

7.  Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease.

Authors:  Raghdaa Hamdan Al Zarzour; Mohammed A Alshawsh; Muhammad Asif; Majed Ahmed Al-Mansoub; Zahurin Mohamed; Mariam Ahmad; Amin Malik Shah Abdul Majid; Mohd Zaini Asmawi; Gurjeet Kaur; Dhamraa Waleed Al-Dualimi; Mun Fei Yam
Journal:  Nutrients       Date:  2018-08-09       Impact factor: 5.717

8.  Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).

Authors:  Monika Pazgan-Simon; Michał Kukla; Jolanta Zuwała-Jagiełło; Aleksandra Derra; Martyna Bator; Tomasz Menżyk; Andrzej Lekstan; Ewa Grzebyk; Krzysztof Simon
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

9.  Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells.

Authors:  Ning Wang; Qihe Xu; Hor Yue Tan; Ming Hong; Sha Li; Man-Fung Yuen; Yibin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-30       Impact factor: 2.629

Review 10.  Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract.

Authors:  Aleksandra Derra; Martyna Bator; Tomasz Menżyk; Michał Kukla
Journal:  Clin Exp Hepatol       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.